Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 811 results for "Treatment For Ovarian Cancer"

Olaparib approved in the EU as treatment for advanced BCRA-mutated ovarian cancer
Ecancer Medicalscience

Olaparib Approved in Europe for BRCA Ovarian Cancer

The first-in-class drug olaparib ( Lynparza , AstraZeneca) has now been granted marketing authorization by the European Commission (EC), following the recommendation for approval that it received in October from the European Medicines Agency. The EC ... General Medicine eJournal, 1 hour ago

29 images for Treatment For Ovarian Cancer

Florida Times-Union, 4 weeks ago
Miami Herald, 1 month ago
MedIndia, 2 months ago
Sys-Con Media, 1 week ago
Med India, 3 weeks ago, 6 days ago
ALN, 3 weeks ago
Pharmafocus, 17 hours ago
Invezz, 18 hours ago
Ecancer Medicalscience, 16 hours ago

AstraZeneca cancer drug cleared in Europe

News Editor The European Commission approves AstraZeneca's (NYSE:AZN) Lynparza (olaparib) for the maintenance treatment of adult patients with platinum-resistant relapsed BRCA-mutated (germline and/or somatic) high grade serious epithelial ...
 Seeking Alpha16 hours ago AstraZeneca ovarian cancer drug approved in Europe  Pharmafocus17 hours ago AstraZeneca's Lynparza has received European Union approval as first-in-class treatment for BRCA-mutated ovarian cancer. AstraZeneca said the European Commission has granted marketing authorisation for Lynparza (olaparib) capsules (400mg twice daily) as t  Money Week19 hours ago LYNPARZAT APPROVED IN THE EUROPEAN UNION  TrustNet21 hours ago
Pharma Letter

'Reducing oestrogen levels could hold key to breast cancer treatment'

An on-going international clinical trial, of which Tata Memorial Centre (TMC) in Parel is a partner, may change the way breast cancer is being treated in menstruating women. The study has shown that chances of recurrence of breast cancer reduce ...
 Hindustan Times12 hours ago IBCSG Presents Phase 3 Results Evaluating the Use of Ovarian Suppression to Adjuvant Treatment with Tamoxifen  Individual.com2 days ago New Algorithm for Treatment of Premenopausal Breast Cancer  Medscape6 days ago Ipsen Announces That Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen  BioSpace6 days ago

AstraZeneca's blockbuster cancer drug gains EU approval

AstraZeneca has gained approval to market its blockbuster ovarian cancer drug Lynparza across Europe. The orally taken drug is used to treat specific strains of ovarian cancer, particularly mutated or relapsed forms of the disease, and the ...
 Citywire20 hours ago AstraZeneca snags EU approval for first-in-class cancer fighter Lynparza  FiercePharma12 hours ago EU okays AstraZeneca's ovarian cancer treatment  Invezz18 hours ago EU regulator clears AstraZeneca's Lynparza for ovarian cancer  FirstWord Pharma19 hours ago
Health Finder

New breast cancer treatment shows promise for women below 35

A five-year international study has now affirmed that certain treatment regimes are more effective in putting a brake on recurrence of breast cancer in women aged below 35. Who conducted the study? The study was conducted by International Breast Cancer Study ...
 DNA1 day ago New Breast Cancer Treatment Promising for Some  WebMD1 week ago New Treatment Shows Promise in Younger Breast Cancer Patients: Study  Health Finder1 week ago Patent Application Titled "Stable Nanoemulsions Useful in the Treatment of Cancer" Published Online  4 Traders2 weeks ago

Immunovaccine receives FDA fast track status for DPX-Survivac to treat ovarian cancer

Immunovaccine, a clinical stage vaccine and immunotherapy company, announced that DPX-Survivac, the company's lead cancer vaccine candidate, has been granted fast track designation by the US Food and Drug Administration (FDA) as maintenance therapy ...
 Pharmaceutical Business Review3 days ago US FDA grants fast tract status to Immunovaccine's DPX-Survivac for ovarian cancer treatment  PharmaBiz6 days ago Immunovaccine Gets FDA Fast Track Status For DPX-Survivac For Ovarian Cancer  RTTNews.com1 week ago Immunovaccine : Receives FDA Fast Track Designation for DPX-Survivac for Treatment of Ovarian Cancer  4 Traders1 week ago
MedPage Today

Premenopausal women who received ovarian suppression treatment along with tamoxifen had a lower risk of breast cancer recurrence

Find News Releases For:keyword Between these dates: select start Month Jan. Feb. Mar. Apr. May Jun. Jul. Aug. Sept. Oct. Nov. Dec. select start Year 19981999200020012002200320042005200620072008200920102011201220132014 select end Month Jan.
 National Cancer Institute2 days ago Perfecting Breast-Cancer Treatment — Incremental Gains and Musculoskeletal Pains  New England Journal of Medicine6 days ago Adjuvant Ovarian Suppression in Premenopausal Breast Cancer  New England Journal of Medicine6 days ago Ovarian suppression reduces recurrence for some young breast cancer patients  Medical News Today6 days ago
Med India

Antiangiogenic Treatment Improves Survival of Mice Models of Ovarian Cancer

A new antiangiogenic treatment with 3TSR has been shown to shrink tumors and improves effectiveness of chemotherapy. Epithelial ovarian cancer is the most lethal cancer of the female reproductive organs, with more than 200,000 new cases and more ...
 Biotech Daily1 week ago Animal Study Finds Antiangiogenic Treatment Improves Survival in Ovarian Cancer  Med India3 weeks ago

Susan Poorman Blackie Ovarian Cancer Foundation Celebrates Founder's Legacy With Pledge

HOUSTON, Dec. 9, 2014 /PRNewswire/ -- Susan Poorman Blackie Ovarian Cancer Foundation (SPB4OVC), based in Houston, today announces its two-year, $100,000-per-year pledge to The Clearity Foundation in San Diego. SPB4OVC is an organization with a ...
 Financial Content1 week ago

PharmaMar reports Phase IIb data for overall survival of PM1183 in platinum-resistant ovarian cancer

04/12/14/10/27 Eureka Alerts 1 Global ( Pharmamar ) Platinum-resistant ovarian cancer patients treated with PM1183 had superior median overall survival compared to topotecan. In this group of 33 randomized patients, treatment with PM1183 showed ...
 Infrosoft2 weeks ago Zeltia : PharmaMar reports Phase IIb results for PM1183 showing a median overall survival of 18.1 months compared to 8.5 months for topotecan in platinum-resistant ovarian cancer patients  4 Traders2 weeks ago PharmaMar reports Phase IIb results for PM1183 showing a median overall survival of 18.1 months compared to 8.5 months for topotecan in platinum-resistant ovarian cancer patients  PipelineReview1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less